These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20493213)

  • 21. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effects of atypical antipsychotics.
    Wirshing DA
    J Clin Psychiatry; 2001; 62 Suppl 21():7-10. PubMed ID: 11584988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic-associated weight gain and clinical outcome parameters.
    Blin O; Micallef J
    J Clin Psychiatry; 2001; 62 Suppl 7():11-21. PubMed ID: 11346191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration.
    Baptista T; Lacruz A; Angeles F; Silvera R; de Mendoza S; Mendoza MT; Hernández L
    Pharmacopsychiatry; 2001 Nov; 34(6):223-31. PubMed ID: 11778142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal glucose metabolism in patients treated with antipsychotics.
    Scheen AJ; De Hert MA
    Diabetes Metab; 2007 Jun; 33(3):169-75. PubMed ID: 17412628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
    Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
    Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atypical antipsychotics and diabetes mellitus.
    Lichiardopol R
    Rom J Intern Med; 2004; 42(2):301-12. PubMed ID: 15529621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.
    Citrome LL; Holt RI; Zachry WM; Clewell JD; Orth PA; Karagianis JL; Hoffmann VP
    Ann Pharmacother; 2007 Oct; 41(10):1593-603. PubMed ID: 17785613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antipsychotic-induced weight gain--pharmacogenetic studies].
    Olajossy-Hilkesberger L; Godlewska B; Marmurowska-Michałowskal H; Olajossy M; Landowski J
    Psychiatr Pol; 2006; 40(5):1009-20. PubMed ID: 17217242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular pathophysiology of metabolic effects of antipsychotic medications.
    Ballon JS; Pajvani U; Freyberg Z; Leibel RL; Lieberman JA
    Trends Endocrinol Metab; 2014 Nov; 25(11):593-600. PubMed ID: 25190097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics.
    Hägg S; Söderberg S; Ahrén B; Olsson T; Mjörndal T
    J Clin Psychiatry; 2001 Nov; 62(11):843-8. PubMed ID: 11775042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical models of antipsychotic drug-induced metabolic side effects.
    Boyda HN; Tse L; Procyshyn RM; Honer WG; Barr AM
    Trends Pharmacol Sci; 2010 Oct; 31(10):484-97. PubMed ID: 20674990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.
    Coccurello R; Moles A
    Curr Protoc Neurosci; 2010 Jul; Chapter 9():Unit9.33. PubMed ID: 20578036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system.
    Leung JY; Barr AM; Procyshyn RM; Honer WG; Pang CC
    Pharmacol Ther; 2012 Aug; 135(2):113-22. PubMed ID: 22565090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antipsychotic-induced weight gain.
    Goudie AJ; Cooper GD; Halford JC
    Diabetes Obes Metab; 2005 Sep; 7(5):478-87. PubMed ID: 16050940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children.
    Devlin AM; Panagiotopoulos C
    Pharmacogenomics; 2015; 16(9):981-96. PubMed ID: 26107755
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.